Compare AbCellera Biologics Inc (ABCL) vs ING Groep NV (ING) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs ING Groep NV — how do they compare? AbCellera Biologics Inc trades at $7.11 (market cap $2.35B), while ING Groep NV trades at $31.94 (market cap $92.35B). The key difference: ING Groep NV is far larger — about 39.3× AbCellera Biologics Inc's market cap, and ING Groep NV pays a 3.93% dividend while AbCellera Biologics Inc pays none. Which is the better fit depends on your goals.
| ABCL | ING | |
|---|---|---|
Market Cap | $2.35B | $92.35B |
Sector | Health | Financials |
52-Week High | $8.12 | $32.96 |
52-Week Low | $2.78 | $22.45 |
Enterprise Value | $1.99B | — |
Dividend Yield | — | 3.93% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
ING trades at $32.24, up 0.44% today, with a bullish technical outlook supported by moving averages. The stock shows consistent earnings beats and a 27.84% net income margin. Recent news highlights strategic moves like a global subscription banking model and board appointments, reinforcing growth initiatives. Analyst consensus is strongly positive with 62.5% buy ratings.
The outlook remains favorable due to solid fundamentals and bullish sentiment, though risks include volatile cash flows and macroeconomic pressures. Upside potential is supported by a DCF intrinsic value of $34, suggesting modest appreciation from current levels. Investors should weigh strong profitability against sector-specific headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About ING Groep NV
The merger of the Dutch postal bank and NN Insurance in 1991 created ING. Through a series of further acquisitions ING build up a global footprint. The 2008 financial crisis forced ING to seek government support--a precondition of which was that ING should separate its banking and insurance activities, which saw ING revert to being solely a bank. ING has market- leading banking operations in the Netherlands and Belgium, and a range of digital banks across Europe and Australia. Its global wholesale banking operation is primarily focused on lending.
Read more on ING →
